NCT02209324View on ClinicalTrials.gov

Open-label Study of ASP2151 in Herpes Simplex Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

August 20, 2015

Conditions
Herpes Simplex
Interventions
DRUG

ASP2151

Trial Locations (3)

Unknown

Sapporo Hokkaido Japan, Sapporo

Oota-ku Tokyo Japan, Tokyo

Yokohama Kanagawa Japan, Yokohama

All Listed Sponsors
lead

Maruho Co., Ltd.

INDUSTRY

NCT02209324 - Open-label Study of ASP2151 in Herpes Simplex Patients | Biotech Hunter | Biotech Hunter